Skip to main content
Journal cover image

Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.

Publication ,  Journal Article
Suzuki, A; Yuen, N; Walsh, J; Papay, J; Hunt, CM; Diehl, AM
Published in: Clin Gastroenterol Hepatol
August 2009

BACKGROUND & AIMS: Acetaminophen-induced liver injury is the most common cause of acute liver failure in the United States; it occurs inadvertently in approximately half of all cases. Concomitant use of other medications might impact susceptibility to acetaminophen hepatotoxicity. We investigated its association with administration of drugs that have been shown to modulate liver injury and/or repair in preclinical studies. METHODS: We analyzed data from 6386 cases of acetaminophen-associated liver injury that were defined in the FDA database of reported adverse events. Data reported in the severe adverse event categories of "died" or "life-threatening" (defined as "fatal" cases, n = 2512) were compared with those of "non-fatal" cases (n = 3874). Potential associations between fatality and concomitant use of 9 drug classes were assessed using multiple logistic regression analyses after adjusting for other variables. RESULTS: Among female subjects, concomitant use of statins, fibrates or nonsteroidal anti-inflammatory drugs was associated with decreased likelihood of fatality, whereas ethanol use was associated with increased likelihood. Among male subjects, concomitant use of statins was associated with decreased likelihood of fatality, whereas concomitant use of sympathetic stimulants or ethanol was associated with increased likelihood. Concomitant use of angiotensin converting enzyme inhibitors or angiotensin receptor II antagonists was associated with decreased likelihood of fatality among younger subjects. CONCLUSIONS: Concomitant use of medications that have been shown in preclinical studies to modulate liver injury and/or repair influenced acetaminophen hepatotoxicity. Drugs that reduce injury or increase repair are protective, whereas those that exacerbate injury or reduce repair are detrimental.

Duke Scholars

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

August 2009

Volume

7

Issue

8

Start / End Page

882 / 888

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Middle Aged
  • Male
  • Liver Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Ethanol
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Suzuki, A., Yuen, N., Walsh, J., Papay, J., Hunt, C. M., & Diehl, A. M. (2009). Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol, 7(8), 882–888. https://doi.org/10.1016/j.cgh.2009.03.034
Suzuki, Ayako, Nancy Yuen, John Walsh, Julie Papay, Christine M. Hunt, and Anna Mae Diehl. “Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.Clin Gastroenterol Hepatol 7, no. 8 (August 2009): 882–88. https://doi.org/10.1016/j.cgh.2009.03.034.
Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol. 2009 Aug;7(8):882–8.
Suzuki, Ayako, et al. “Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.Clin Gastroenterol Hepatol, vol. 7, no. 8, Aug. 2009, pp. 882–88. Pubmed, doi:10.1016/j.cgh.2009.03.034.
Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol. 2009 Aug;7(8):882–888.
Journal cover image

Published In

Clin Gastroenterol Hepatol

DOI

EISSN

1542-7714

Publication Date

August 2009

Volume

7

Issue

8

Start / End Page

882 / 888

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Middle Aged
  • Male
  • Liver Diseases
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Ethanol